Evidence map›Paper›PMID 31316070›Full record

ArticleNature communications2019

Inactivating mutations and X-ray crystal structure of the tumor suppressor OPCML reveal cancer-associated functions.

James R Birtley, Mohammad Alomary, Elisa Zanini, Jane Antony, Zachary Maben, Grant C Weaver, Claudia Von Arx, Manuela Mura, Aline T Marinho, Haonan Lu and 8 more

Open access · goldAbstract read
In one paragraph

Article in Nature communications, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Downregulation ofFrontiers in oncology · 2025
    Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Cancer genomics & proteomics
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 4 institutions in 3 countries.

James R BirtleyDepartment of Pathology, University of Massachusetts Medical School, Worcester, MA, 01655, USA.
Mohammad AlomaryOvarian Cancer Action Research Centre, Department of Surgery and Cancer, Imperial College London, Du Cane Road, London, W12 0NN, UK.
Elisa ZaniniOvarian Cancer Action Research Centre, Department of Surgery and Cancer, Imperial College London, Du Cane Road, London, W12 0NN, UK.
Jane AntonyOvarian Cancer Action Research Centre, Department of Surgery and Cancer, Imperial College London, Du Cane Road, London, W12 0NN, UK.ORCID http://orcid.org/0000-0002-2424-5470
Zachary MabenDepartment of Pathology, University of Massachusetts Medical School, Worcester, MA, 01655, USA.
Grant C WeaverDepartment of Pathology, University of Massachusetts Medical School, Worcester, MA, 01655, USA.ORCID http://orcid.org/0000-0003-1151-2944
Claudia Von ArxOvarian Cancer Action Research Centre, Department of Surgery and Cancer, Imperial College London, Du Cane Road, London, W12 0NN, UK.
Manuela MuraOvarian Cancer Action Research Centre, Department of Surgery and Cancer, Imperial College London, Du Cane Road, London, W12 0NN, UK.
Aline T MarinhoOvarian Cancer Action Research Centre, Department of Surgery and Cancer, Imperial College London, Du Cane Road, London, W12 0NN, UK.
Haonan LuOvarian Cancer Action Research Centre, Department of Surgery and Cancer, Imperial College London, Du Cane Road, London, W12 0NN, UK.ORCID http://orcid.org/0000-0002-2472-7488
Eloise V N MorecroftOvarian Cancer Action Research Centre, Department of Surgery and Cancer, Imperial College London, Du Cane Road, London, W12 0NN, UK.
Evdoxia KaraliOvarian Cancer Action Research Centre, Department of Surgery and Cancer, Imperial College London, Du Cane Road, London, W12 0NN, UK.
Naomi E ChayenComputational and Systems Medicine, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, London, SW7 2AZ, UK.ORCID http://orcid.org/0000-0003-2861-2458
Edward W TateDepartment of Chemistry, Imperial College London, Wood Lane, London, W12 0BZ, UK.ORCID http://orcid.org/0000-0003-2213-5814
Mollie JurewiczDepartment of Pathology, University of Massachusetts Medical School, Worcester, MA, 01655, USA.
Lawrence J SternDepartment of Pathology, University of Massachusetts Medical School, Worcester, MA, 01655, USA. lawrence.stern@umassmed.edu.ORCID http://orcid.org/0000-0001-9870-8557
Chiara RecchiOvarian Cancer Action Research Centre, Department of Surgery and Cancer, Imperial College London, Du Cane Road, London, W12 0NN, UK. c.recchi@imperial.ac.uk.ORCID http://orcid.org/0000-0003-1605-0945
Hani GabraOvarian Cancer Action Research Centre, Department of Surgery and Cancer, Imperial College London, Du Cane Road, London, W12 0NN, UK. h.gabra@imperial.ac.uk.ORCID http://orcid.org/0000-0002-3322-4399
Ovarian Cancer Action · GBUniversity of Massachusetts Chan Medical School · USImperial College London · GBAstraZeneca (United Kingdom) · GB

Funding

TRAINING IN IMMUNOLOGY (COMPETITIVE RENEWAL OF AI07439)T32AI007349 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI STERN, LAWRENCE J. · 1989 to 2024
$4.5M
Structure and Function of MHC ProteinsR37AI038996 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI STERN, LAWRENCE J. · 2008 to 2017
$4.1M
Structure and Function of Class II MHC ProteinsR01AI038996 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI STERN, LAWRENCE J · 1996 to 2006
$1.6M
Structure and Function of Class II MHC ProteinsR56AI038996 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI STERN, LAWRENCE J · 2007 to 2007
$324k
NIAID NIH HHS R01 AI038996NIAID NIH HHS R37 AI038996NIAID NIH HHS R56 AI038996NIAID NIH HHS T32 AI007349
6 · The paper itself

Abstract

OPCML, a tumor suppressor gene, is frequently silenced epigenetically in ovarian and other cancers. Here we report, by analysis of databases of tumor sequences, the observation of OPCML somatic missense mutations from various tumor types and the impact of these mutations on OPCML function, by solving the X-ray crystal structure of this glycoprotein to 2.65 Å resolution. OPCML consists of an extended arrangement of three immunoglobulin-like domains and homodimerizes via a network of contacts between membrane-distal domains. We report the generation of a panel of OPCML variants with representative clinical mutations and demonstrate clear phenotypic effects in vitro and in vivo including changes to anchorage-independent growth, interaction with activated cognate receptor tyrosine kinases, cellular migration, invasion in vitro and tumor growth in vivo. Our results suggest that clinically occurring somatic missense mutations in OPCML have the potential to contribute to tumorigenesis in a variety of cancers.

Indexed as

Epigenesis, GeneticCell Adhesion MoleculesCell Transformation, NeoplasticCrystallography, X-RayFemaleGlycosylationGPI-Linked ProteinsHumansMutation, MissenseNeoplasm InvasivenessOvarian NeoplasmsProtein Aggregation, PathologicalProtein Structure, TertiaryCell Adhesion MoleculesGPI-Linked ProteinsOPCML protein, human

Identifiers

PMID31316070
PMCPMC6637204
OpenAlexW2960723617

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.